FDA OKs Combination for Low-Grade Serous Ovarian Cancer

(MedPage Today) -- The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian cancer who have received prior...